What's Happening?
SpinaFX Medical has received an Investigational Device Exemption (IDE) from the FDA to conduct a pivotal clinical trial in the U.S. for its Triojection® treatment. This minimally invasive, image-guided therapy involves an intradiscal ozone/oxygen injection
combined with a nerve root block for patients with contained herniated lumbar discs. The trial will enroll 300 patients across 30 sites to evaluate the treatment's effectiveness compared to nerve root block alone. This marks a significant step in addressing the therapeutic gap between conservative care and surgery for lumbar disc herniation.
Why It's Important?
The IDE approval is a crucial milestone for SpinaFX Medical, as it allows the company to gather clinical evidence needed for potential FDA marketing authorization. The treatment addresses a significant unmet need in spine care, offering a less invasive alternative to surgery for patients who do not respond to conservative treatments. If successful, this could lead to a new standard of care for lumbar disc herniation, reducing healthcare costs and improving patient outcomes.
What's Next?
The clinical trial will focus on safety, effectiveness, and health economics, with primary and secondary endpoints including pain and function measures over 24 months. The results will determine whether the treatment can be marketed in the U.S. and potentially influence reimbursement and clinical practice guidelines. SpinaFX will continue to collaborate with clinical sites and partners to ensure the trial's success.
